These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 7285323)

  • 1. Many hitherto unknown peptides are principal constituents of uremic "middle molecules".
    Menyhárt J; Gróf J
    Clin Chem; 1981 Oct; 27(10):1712-6. PubMed ID: 7285323
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Determination of endogenous middle molecules in normal and uremic body fluids.
    Fürst P; Zimmerman L; Bergström J
    Clin Nephrol; 1976 Apr; 3(2):178-88. PubMed ID: 1277595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bound amino acids in uremic sera: search for peptidic middle molecules by preparative polyacrylamide gel electrophoresis and high performance liquid chromatography.
    Kaplan B; Gotfried M; Cojocaru M; Pras M; Ravid M
    Clin Chim Acta; 1989 Nov; 185(2):119-30. PubMed ID: 2624993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Middle-sized ninhydrin-positive molecules in uraemic patients treated by repeated haemodialysis. II. Chief peptide constituents of the faction.
    Klein A; Sarnecka-Keller M; Hanicki Z
    Clin Chim Acta; 1978 Nov; 90(1):7-11. PubMed ID: 719891
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amino acid composition of uremic middle and low molecular weight retention products.
    Bazilinski N; Shaykh M; Ahmed S; Musiala T; Williams RH; Poulos A; Dubin A; Dunea G
    Adv Exp Med Biol; 1987; 223():197-204. PubMed ID: 3447436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Study of middle molecules with positive reaction to ninhydrin present in uremic and normal blood and their isolation].
    Buzio C; Dall'Aglio PP; Delmonte G; Montagna G; Migone L
    Minerva Nefrol; 1979; 26(1):45-8. PubMed ID: 471320
    [No Abstract]   [Full Text] [Related]  

  • 7. Molecular weight distribution, diffusibility and comparability of middle molecular fractions prepared from normal and uremic sera by different fractionation procedures.
    Gróf J; Menyhárt J
    Nephron; 1982; 30(1):60-7. PubMed ID: 7088233
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Separation of six uremic middle molecular compounds by high performance liquid chromatography and analysis by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry.
    Chu J; Yuan Z; Liu X; Wu Q; Mi H; He B
    Clin Chim Acta; 2001 Sep; 311(2):95-107. PubMed ID: 11566169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Middle molecules in uremic serum, urine and dialysis fluid.
    Migone L; Dall'taglio P; Buzio C
    Clin Nephrol; 1975; 3(3):82-93. PubMed ID: 1139803
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Amino acid composition of peptides with molecular weight between 500 and 1500 daltons isolated from uremic and normal sera].
    Montagna G; Buzio C; Del Monte G; Manari A; Migone L
    Minerva Nefrol; 1980; 27(2):383-6. PubMed ID: 7219861
    [No Abstract]   [Full Text] [Related]  

  • 11. Influence of uremic middle molecules on blood cells.
    Ota K; Sanaka T; Agishi T; Nakajima O
    Artif Organs; 1980 May; 4(2):113-5. PubMed ID: 7396763
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Separation, identification of uremic middle molecules, and preliminary study on their toxicity.
    Li G; Chu J; Liu X; Yuan Z
    Clin Chim Acta; 2004 Dec; 350(1-2):89-98. PubMed ID: 15530464
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Separation, isolation and amino acid composition of uremic peptides.
    Shaykh M; Dubin A; Dunea G; Mamdani B; Ahmed S
    Clin Physiol Biochem; 1984; 2(1):1-13. PubMed ID: 6488692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medium-sized peptides in the blood of patients with uremia.
    Mabuchi H; Nakahashi H
    Nephron; 1983; 33(4):232-7. PubMed ID: 6843753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of beta-aminoisobutyric acid in uremic serum.
    Gejyo F; Kinoshita Y; Ikenaka T
    Clin Chim Acta; 1976 Aug; 70(3):407-15. PubMed ID: 947634
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Isolation and identification of canine plasma components suspected as uremic toxins.
    Kawamura M; Ohashi F; Nagata Y; Takai N; Motoie H; Nishimura R; Sasaki N; Takeuchi A
    J Vet Med Sci; 1993 Apr; 55(2):265-70. PubMed ID: 8513007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ascorbic acid derivatives in two different fractions of uremic toxins.
    Gallice PM; Monti JP; Braguer DL; Baz M; Elsen RE; Berland YF; Crevat AD
    Int J Artif Organs; 1991 Dec; 14(12):754-8. PubMed ID: 1783448
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Uremic middle molecules: analytical study of middle molecular weight fractions subpeak b4-2.
    Le Moel G; Strecker G; Cueille G; Boudet J; Man NK; Galli A; Agneray J
    Artif Organs; 1981; 4 Suppl():17-21. PubMed ID: 7295087
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of uremic "middle molecular" fractions by gas chromatography, mass spectrometry, isotachophoresis, and liquid chromatography.
    Schoots AC; Mikkers FE; Claessens HA; De Smet R; Van Landschoot N; Ringoir SM
    Clin Chem; 1982 Jan; 28(1):45-9. PubMed ID: 7055936
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Uremic middle molecules exist and are biologically active.
    Bergström J; Fürst P; Zimmerman L
    Clin Nephrol; 1979 May; 11(5):229-38. PubMed ID: 455821
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.